Bronfman E.L. Rothschild L.P. grew its stake in Qiagen NV (NASDAQ:QGEN) by 74.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 19,807 shares of the company’s stock after buying an additional 8,445 shares during the period. Bronfman E.L. Rothschild L.P.’s holdings in Qiagen were worth $750,000 at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. Parallel Advisors LLC boosted its holdings in shares of Qiagen by 548.5% in the 3rd quarter. Parallel Advisors LLC now owns 3,210 shares of the company’s stock valued at $122,000 after buying an additional 2,715 shares in the last quarter. Prudential Financial Inc. acquired a new position in shares of Qiagen in the 3rd quarter valued at $206,000. Gideon Capital Advisors Inc. purchased a new stake in Qiagen in the 3rd quarter valued at $213,000. Private Trust Co. NA purchased a new stake in Qiagen in the 3rd quarter valued at $233,000. Finally, Lourd Capital LLC purchased a new stake in Qiagen in the 3rd quarter valued at $250,000. Institutional investors and hedge funds own 62.23% of the company’s stock.
Several analysts recently commented on QGEN shares. BidaskClub downgraded shares of Qiagen from a “hold” rating to a “sell” rating in a research report on Saturday, August 18th. Commerzbank reiterated a “buy” rating on shares of Qiagen in a research report on Wednesday, August 29th. Barclays reiterated a “buy” rating and issued a $43.00 price target on shares of Qiagen in a research report on Thursday, September 6th. Deutsche Bank set a $44.00 price target on shares of Qiagen and gave the company a “buy” rating in a research report on Friday, October 5th. Finally, Morgan Stanley upped their price target on shares of Qiagen from $38.00 to $39.00 and gave the company an “overweight” rating in a research report on Wednesday, October 10th. Eight investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $39.13.
QGEN stock opened at $35.43 on Thursday. Qiagen NV has a 12 month low of $30.64 and a 12 month high of $39.45.
Qiagen (NASDAQ:QGEN) last announced its quarterly earnings data on Monday, October 29th. The company reported $0.35 EPS for the quarter, topping the Zacks’ consensus estimate of $0.33 by $0.02. The firm had revenue of $377.90 million for the quarter, compared to analysts’ expectations of $380.11 million. The firm’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.32 EPS.
ILLEGAL ACTIVITY NOTICE: This piece was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/12/06/qiagen-nv-qgen-shares-bought-by-bronfman-e-l-rothschild-l-p.html.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
See Also: What is a Tariff?
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.